Maravai LifeSciences Holdings

MRVI · NASDAQ

$7.20+$0.21 (+3.00%)TodayMarket closed · Oct 20, 7:50 PM ET

Prev close $6.99

MRVI analyst rating

BuyConsensus of 3 analysts over the last 12 months. 67% rate it a buy.

Strong buy0
Buy2
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $7.75 (+7.7% upside)

Low: $7.07
Now: $7.20
High: $8.40

Upgrades and downgrades

The latest rating actions, newest first

MRVI analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Sep 9, 2026	Maintains	Neutral	$2.50 → $8.00	61%
Wells Fargo	Aug 7, 2026	Maintains	Overweight	$5.50 → $6.50	100%
Wells Fargo	May 8, 2026	Maintains	Overweight	$4.50 → $5.50	66%
Wells Fargo	Dec 15, 2025	Maintains	Overweight	$4.00 → $4.50	66%

The case for and against

Updated Nov 27, 2024

Bull case

Maravai LifeSciences Holdings Inc is positioned for significant financial growth, with expectations of increasing revenue by over $10 million in FY'25, driven by improving end-markets and a notable uptick in FDA approvals that enhance the development pipeline. The company benefits from its best-in-class product differentiation, particularly with its CleanCap technology, which is gaining traction in both current and future mRNA programs, reflecting its strategic advantage in the life sciences sector. Additionally, Maravai's strong financial health is bolstered by its participation in high-profile COVID vaccine programs, resulting in solid double-digit sales growth and an impressive recurring revenue mix that supports robust profitability.

Bear case

Maravai LifeSciences is experiencing a negative outlook primarily due to expected flat to slightly lower gross margins influenced by an unfavorable product mix and significant revenue declines from its nucleic acid production segment, projected to be down approximately 8% amid decreased demand for high-volume GMPCleanCap products. Additionally, softness in the Chinese market negatively impacted Q2 results, contributing about $2 million in losses, compounding challenges within the broader bioprocessing space. Furthermore, management’s guidance for full-year revenues indicates a decline of around 5% year-over-year, raising concerns about the company's long-term growth prospects, particularly if there is a total decline in COVID-related program sales which could adversely affect earnings estimates.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.